New
Pune-based startup Ahammune Biosciences has recently completed the phase 1 clinical trials of its investigational new drug AB1001, being developed as a topical therapy for vitiligo.
Dr T. Balganesh, Chairman of Ahammune’s Board said, “Vitiligo is a much neglected disease and specific treatments for the disease are not available. AB1001 is a novel class of compounds, discovered and developed at Ahammune, that has the potential to not only limit the progression of the disease but also reverses the pigmentation loss. The successful completion of Phase 1 of the molecule brings a much wanted treatment closer to the patients. We are looking forward to the compound becoming a drug shortly.”
Ahammune Biosciences and Ahmedabad-based Veeda Clinical Research had partnered for the first in human studies with Ahammune’s investigational new drug AB1001.
FAQOther Questions
- Red Wine and Vitiligo
Recent research has revealed intriguing findings about the potential protective effects of red wine against vitiligo, using a genetic approach to study health outcomes. Red Win...
- Awareness Days Similar to World Vitiligo Day
World Vitiligo Day, celebrated annually on June 25 since 2012, is a significant event dedicated to raising awareness about vitiligo and supporting those affected by the conditio...
- How to get insurance coverage for vitiligo treatments?
Getting insurance coverage for vitiligo treatments can be challenging, but there are several steps you can take to improve your chances For a more in-depth look, check out our ...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.